A Single-centered, Open-labeled, Phase 4 Study of a Northern Hemisphere 2013-2014 Seasonal Trivalent Influenza Inactivated Vaccine, Anflu®

NCT02269852 Phase 4 COMPLETED

The purpose of this study is to evaluate the immunogenicity and safety of Northern hemisphere 2013-2014 seasonal trivalent inactivated influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60 years old, and 60 healthy seniors aged \> 60 years.

Details

Lead sponsor	Sinovac Biotech Co., Ltd
Phase	Phase 4
Status	COMPLETED
Enrolment	182
Start date	2013-12
Completion	2014-06

Conditions

• Influenza

Interventions

• trivalent seasonal influenza vaccine

Primary outcomes

• The immunogenicity of 2013-2014 seasonal trivalent vaccine (TIV) in adults and seniors — 21 days after vaccination
  To evaluate the immune responses to each antigen of the 2013-2014 seasonal TIV in adults and seniors by detection of hemagglutination inhibition (HI) antibody titer

Countries

China